Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy

Read More

NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing

Read More

Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs

Read More

Ryvu Therapeutics at BIO Digital 2020

Read More

Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference

Read More

Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II

Read More

Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress

Read More

Galapagos and Ryvu announce research collaboration

Read More

Ryvu Therapeutics Reports Annual 2019 Financial Results

Read More

Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference

Read More